SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGraft Polymer PLC Regulatory News (GPL)

  • There is currently no data for GPL

Director/PDMR Shareholding

8 Jan 2024 17:00

RNS Number : 9916Y
Graft Polymer (UK) PLC
08 January 2024

8 January 2024

PDMR Share Dealing

Graft Polymer (UK) Plc ("Company") announces that on 4 January 2024, ordinary shares of £0.001 each in the Company ("Ordinary Shares") were disposed of by a person discharging managerial responsibility ("PDMR") in the Company as listed below.

Name

Role

Nature of transaction

Number of Ordinary Shares

Victor Bolduev

Chief Executive Officer, Director

Transfer of Ordinary Shares

10,750,000

It is further announced that on 4 January 2024, Ordinary Shares were subscribed for (subject to various conditions being met, including approval by the FCA, and publication, of a prospectus ("Conditions")) ("Subscription") by certain PDMRs and persons closely associated with PDMRs as listed below.

Name

Role

Nature of transaction

Number of Ordinary Shares

Victor Bolduev

Chief Executive Officer, Director

Conditional subscription for Ordinary Shares

22,529,1661

Roby Zomer

Chairman, Director

Conditional subscription for Ordinary Shares

11,111,000

Yifat Steuer

Chief Financial Officer, Director

Conditional subscription for Ordinary Shares

11,711,167

Pavel Kobzev

Chief Marketing Officer, Director

Conditional subscription for Ordinary Shares

8,694,0002

Alexander Brooks

Director

Conditional subscription for Ordinary Shares

2,810,667

Anthony Eastman

Company Secretary

Conditional subscription for Ordinary Shares

2,810,6673

1 Of which 11,760,333 Ordinary Shares were subscribed for by Polymer Innovations Inc., a company controlled by Victor Bolduev.

2 Of which 5,675,167 Ordinary Shares were subscribed for by MSW Ltd, a company controlled by Pavel Kobzev.

3 These Ordinary Shares were subscribed for by Tournesol Consulting Ltd, a company controlled by Anthony Eastman.

A further announcement is expected to be made upon the Conditions having been met.

About Graft Polymer

Graft Polymer is a London Stock Exchange listed company (GPL.L) with a cutting-edge, research and development (R&D) and manufacturing facility based in Slovenia which has already introduced more than 50 products to the market. The core business of the Group comprises polymer modification and drug delivery system developments. The Group has developed a proprietary set of polymer modification technologies which uses recycled raw materials and a closed loop system to reduce waste. Graft Polymer's technology can improve existing products and processing methodologies by enhancing performance, simplifying manufacturing, reducing material consumption, widening the choice of feedstocks, and reducing costs.

Graft Polymer has three divisions: polymer modification; IP for Bio/Pharma applications including a drug delivery system (Graft Bio) and the Group's food supplement division. A significant milestone was reached in May 2022 when the Slovenian manufacturing facility was granted a Hazard Analysis and Critical Control Point (HACCP) Certificate. The HACCP Certificate allows it to enter the lucrative Business-to-Consumer market and commercialise its IP for bio/pharma applications, developing active pharmaceutical ingredients and drug delivery platforms for use in the food supplement market, thereby introducing a further revenue stream to its business.

Environment, Social and Governance is at the forefront of the Group's strategy and the facility in Slovenia has been granted ISO 14001 accreditation in recognition of the environmental management systems in place to reduce waste. Graft Polymer only uses REACH and ROHS certificated raw materials instead of toxic raw materials, and its extensive R&D programme has also developed specialised recycling polymer additives which increases the strength of recycled blends and plastic products whilst also reducing plastic waste by between 40 and 50 per cent.

For further information, visit www.graftpolymer.com, follow on Twitter @PolymerLtd or contact:

Graft Polymer (UK) Plc

Roby Zomer, Non-Executive Chairman info@graftpolymer.com

Yifat Steuer, CFO and Executive Director

Notification of dealings in shares by PDMRs of the Company:

1.

Details of PDMR / PDMR Associate

(a)

Name

Victor Bolduev

(b)

Position / status

Chief Executive Officer, Director

(c)

Initial notification /

amendment

Initial notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

(d)

Description of the financial instrument

Ordinary Shares in Graft Polymer (UK) Plc

(e)

Nature of the transaction

Disposal of Ordinary Shares

(f)

Price(s) and volume(s)

Price per Ordinary Share: 0.6 pence

Volume: 10,750,000

(g)

Aggregated information

Aggregated volume

Price

n/a

(h)

Date of the transaction

4 January 2024

(i)

Place of the transaction

London, United Kingdom

1.

Details of PDMR / PDMR Associate

(a)

Name

Victor Bolduev

(b)

Position / status

Chief Executive Officer, Director

(c)

Initial notification /

amendment

Initial notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

(d)

Description of the financial instrument

Ordinary Shares in Graft Polymer (UK) Plc

(e)

Nature of the transaction

Subscription of Ordinary Shares (subject to the Conditions, as defined above, being met)

(f)

Price(s) and volume(s)

Price per Ordinary Share: 0.6 pence

Volume: 10,768,833

(g)

Aggregated information

Aggregated volume

Price

n/a

(h)

Date of the transaction

4 January 2024

(i)

Place of the transaction

London, United Kingdom

1.

Details of PDMR / PDMR Associate

(a)

Name

Polymer Innovations Inc.

(b)

Position / status

Company controlled by Victor Bolduev

(c)

Initial notification /

amendment

Initial notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

(d)

Description of the financial instrument

Ordinary Shares in Graft Polymer (UK) Plc

(e)

Nature of the transaction

Conditional subscription for Ordinary Shares

(f)

Price(s) and volume(s)

Price per Ordinary Share: 0.6 pence

Volume: 11,760,333

(g)

Aggregated information

Aggregated volume

Price

n/a

(h)

Date of the transaction

4 January 2024

(i)

Place of the transaction

London, United Kingdom

1.

Details of PDMR / PDMR Associate

(a)

Name

Roby Zomer

(b)

Position / status

Chairman, Director

(c)

Initial notification /

amendment

Initial notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

(d)

Description of the financial instrument

Ordinary Shares in Graft Polymer (UK) Plc

(e)

Nature of the transaction

Conditional subscription for Ordinary Shares

(f)

Price(s) and volume(s)

Price per Ordinary Share: 0.6 pence

Volume: 11,111,000

(g)

Aggregated information

Aggregated volume

Price

n/a

(h)

Date of the transaction

4 January 2024

(i)

Place of the transaction

London, United Kingdom

1.

Details of PDMR / PDMR Associate

(a)

Name

Yifat Steuer

(b)

Position / status

Chief Financial Officer, Director

(c)

Initial notification /

amendment

Initial notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

(d)

Description of the financial instrument

Ordinary Shares in Graft Polymer (UK) Plc

(e)

Nature of the transaction

Conditional subscription for Ordinary Shares

(f)

Price(s) and volume(s)

Price per Ordinary Share: 0.6 pence

Volume: 11,711,167

(g)

Aggregated information

Aggregated volume

Price

n/a

(h)

Date of the transaction

4 January 2024

(i)

Place of the transaction

London, United Kingdom

1.

Details of PDMR / PDMR Associate

(a)

Name

Pavel Kobzev

(b)

Position / status

Chief Marketing Officer, Director

(c)

Initial notification /

amendment

Initial notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

(d)

Description of the financial instrument

Ordinary Shares in Graft Polymer (UK) Plc

(e)

Nature of the transaction

Conditional subscription for Ordinary Shares

(f)

Price(s) and volume(s)

Price per Ordinary Share: 0.6 pence

Volume: 3,018,833

(g)

Aggregated information

Aggregated volume

Price

n/a

(h)

Date of the transaction

4 January 2024

(i)

Place of the transaction

London, United Kingdom

1.

Details of PDMR / PDMR Associate

(a)

Name

MSW Ltd

(b)

Position / status

Company controlled by Pavel Kobzev

(c)

Initial notification /

amendment

Initial notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

(d)

Description of the financial instrument

Ordinary Shares in Graft Polymer (UK) Plc

(e)

Nature of the transaction

Conditional subscription for Ordinary Shares

(f)

Price(s) and volume(s)

Price per Ordinary Share: 0.6 pence

Volume: 5,675,167

(g)

Aggregated information

Aggregated volume

Price

n/a

(h)

Date of the transaction

4 January 2024

(i)

Place of the transaction

London, United Kingdom

1.

Details of PDMR / PDMR Associate

(a)

Name

Alexander Brooks

(b)

Position / status

Director

(c)

Initial notification /

amendment

Initial notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

(d)

Description of the financial instrument

Ordinary Shares in Graft Polymer (UK) Plc

(e)

Nature of the transaction

Conditional subscription for Ordinary Shares

(f)

Price(s) and volume(s)

Price per Ordinary Share: 0.6 pence

Volume: 2,810,667

(g)

Aggregated information

Aggregated volume

Price

n/a

(h)

Date of the transaction

4 January 2024

(i)

Place of the transaction

London, United Kingdom

1.

Details of PDMR / PDMR Associate

(a)

Name

Tournesol Consulting Ltd

(b)

Position / status

Company controlled by Anthony Eastman

(c)

Initial notification /

amendment

Initial notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

(d)

Description of the financial instrument

Ordinary Shares in Graft Polymer (UK) Plc

(e)

Nature of the transaction

Conditional subscription for Ordinary Shares

(f)

Price(s) and volume(s)

Price per Ordinary Share: 0.6 pence

Volume: 2,810,667

(g)

Aggregated information

Aggregated volume

Price

n/a

(h)

Date of the transaction

4 January 2024

(i)

Place of the transaction

London, United Kingdom

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHFLFFSLSITIIS
12
Date   Source Headline
14th Jan 20257:00 amRNSChange of Name to Solvonis Therapeutics plc
6th Jan 20252:27 pmRNSResult of General Meeting and change of name
16th Dec 20247:00 amRNSProposed acquisition of Awakn Life Sciences Corp
11th Dec 20247:00 amRNSInitial Results University of Nottingham
3rd Dec 20249:44 amRNSNotice of GM and proposed name change
15th Oct 20247:00 amRNSResearch Agreement
4th Oct 20247:00 amRNSResearch and development update
26th Sep 20247:00 amRNSDirectorate Change and grant of options
13th Sep 20247:00 amRNSHalf-year Report
28th Aug 20247:00 amRNSCommercial Collaboration Progress Update
13th Aug 20247:00 amRNSHolding(s) in Company
12th Aug 202410:21 amRNSDirectorate Change
8th Aug 202410:08 amRNSHolding(s) in Company
1st Aug 20247:00 amRNSDirectorate Change
31st Jul 20245:00 pmRNSTotal Voting Rights
23rd Jul 20241:59 pmRNSHolding(s) in Company
23rd Jul 20247:00 amRNSCommercial Collaboration
18th Jul 20247:00 amRNSCommercial Collaboration
17th Jul 20249:28 amRNSHolding(s) in Company
15th Jul 20247:00 amRNSDirectorate Change
12th Jul 20247:00 amRNSHolding(s) in Company
12th Jul 20247:00 amRNSHolding(s) in Company
11th Jul 20249:36 amRNSHolding(s) in Company
11th Jul 20249:27 amRNSHolding(s) in Company
11th Jul 20249:26 amRNSHolding(s) in Company
11th Jul 20249:20 amRNSHolding(s) in Company
11th Jul 20249:20 amRNSHolding(s) in Company
11th Jul 20247:00 amRNSPatent Filings
10th Jul 20244:24 pmRNSHolding(s) in Company
10th Jul 20248:10 amRNSAdmission & Director/PDMR Shareholding
3rd Jul 20242:29 pmRNSPublication of a Prospectus
28th Jun 202412:58 pmRNSResult of AGM
7th Jun 20247:00 amRNSBusiness Update
4th Jun 20244:26 pmRNSNotice of AGM
31st May 20247:00 amRNSPatent Application
28th May 20247:00 amRNSRegulatory Application
9th May 20247:00 amRNSUpdate on recent developments
7th May 20247:00 amRNSGrant of Haemostatic Hydrogel Patent
3rd May 20247:00 amRNSDivestment of Graft Polymer d.o.o – Slo facility
2nd May 20247:00 amRNSReplacement of Chief Executive Officer
30th Apr 20245:05 pmRNSAnnual Financial Report
23rd Apr 20244:17 pmRNSLoan facility update
15th Mar 20247:00 amRNSChairman & Directorate Change & Financial Update
8th Jan 20245:00 pmRNSGM Statement
8th Jan 20245:00 pmRNSHolding(s) in Company
8th Jan 20245:00 pmRNSHolding(s) in Company
8th Jan 20245:00 pmRNSHolding(s) in Company
8th Jan 20245:00 pmRNSHolding(s) in Company
8th Jan 20245:00 pmRNSHolding(s) in Company
8th Jan 20245:00 pmRNSDirector/PDMR Shareholding
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.